Journal
CURRENT CANCER DRUG TARGETS
Volume 12, Issue 3, Pages 279-288Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/156800912799277584
Keywords
Bevacizumab; cilengitide; glioblastoma; resistance; temozolomide; toxicity; VEGF
Categories
Ask authors/readers for more resources
Despite advances in multidisciplinary approaches, the prognosis for most patients with malignant gliomas is poor. Malignant gliomas are highly vascularized tumors with elevated expression of vascular endothelial growth factor (VEGF), an important mediator of angiogenesis. Recent studies of bevacizumab, an anti-VEGF monoclonal antibody, alone or associated with chemotherapy, have demonstrated high response rates and prolongation of median and 6-month progression-free survival. Clinical evaluation of several multitarget small molecule tyrosine kinase inhibitors is ongoing. Other promising antiangiogenic compounds are cilengitide and continuous temozolomide. Toxicity is acceptable. Open issues are represented by patterns of tumor progression, resistance mechanisms and biomarkers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available